1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO) (吲哚胺 2,3 双加氧酶)

Indoleamine 2, 3-dioxygenase (IDO) is an intracellular enzyme that catalyzes the transformation of L-tryptophan to N-formylkynurenine, which is the first and rate-controlling step in the kynurenine pathway.

IDO is a rate-limiting enzyme that catalyzes the degradation of tryptophan into kynurenine and is recognized to exert a tolerizing effect on T cells that require tryptophan to proliferate5. IDO also plays an important role in the activation and regulation of functionally quiescent regulatory T cells.

IDO is a heme-containing enzyme that catalyzes the oxidative cleavage of 2,3 double bond of indole ring. IDO has the ability to inhibit T-cell activation by tryptophan starvation, whereas T-cell survival and proliferation are regulated by O2 free radicals and kynurenine derivatives. IDO plays a crucial role in autoimmunity,infections and malignancies.

Indoleamine-2,3-dioxygenase (IDO) one of the most important immunoregulator enzyme responsible for metabolism of tryptophan as part of Kynurenin pathway. Tryptophan is catabolized in the tumor tissue by the rate-limiting enzyme IDO expressed in tumor cells or antigen presenting cells.

Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

  • IDO1

  • IDO2

  • IDO

Indoleamine 2,3-Dioxygenase (IDO) 相关产品 (16):

Cat. No. Product Name Effect Purity
  • HY-15760
    Necrostatin-1 Inhibitor 99.87%
    Necrostatin-1 (Nec-1) 是一种有效的坏死性凋亡 (necroptosis) 抑制剂,在 Jurkat 细胞中的 EC50 为 490 nM。Necrostatin-1 抑制 RIP1 激酶 (EC50=182 nM) 。Necrostatin-1 (Nec-1) 也是一种 (IDO) 抑制剂。
  • HY-16724
    Indoximod Inhibitor 99.39%
    Indoximod (1-Methyl-D-tryptophan; NLG-8189) 是吲哚胺2,3-双加氧酶 (IDO) 通路抑制剂,Ki 为19 μM。
  • HY-N0110
    Palmatine chloride Inhibitor
    Palmatine chloride 是一种口服活性的不可逆 IDO-1 抑制剂。 Palmatine chloride 可以减轻结肠损伤,预防肠道菌群失调和调节色氨酸分解代谢,从而改善 DSS 诱发的结肠炎。
  • HY-101111
    PF-06840003 Inhibitor 99.79%
    PF-06840003 (EOS200271) 是一种有口服活性的 选择性 IDO-1 抑制剂,抑制 hIDO-1, dIDO-1,和 mIDO-1 的IC50 分别为 0.41 μM, 0.59 μM,和 1.5 μM。
  • HY-N0736
    Coptisine chloride Inhibitor 98.00%
    Coptisine chloride 是从黄连中分离到的生物碱,是一种有效的非竞争性的 IDO 抑制剂,Ki 值为 5.8 μM,IC50 值为 6.3 μM。Coptisine chloride 是一种有效的 H1N1 神经氨酸酶 (NA-1) 抑制剂,IC50 为 104.6 μg/mL,可用于甲型流感病毒 (H1N1) 感染。
  • HY-N0707
    (S)-Indoximod Inhibitor 99.03%
    (S)-Indoximod (1-Methyl-L-tryptophan) 是吲哚胺-2,3-双加氧酶 (IDO) 抑制剂。(S)-Indoximod 可用于癌症研究。
  • HY-133897
    (Rac)-Indoximod Inhibitor 98.13%
    (Rac)-Indoximod (1-Methyl-DL-tryptophan) 是吲哚胺-2,3-双加氧酶 (IDO) 抑制剂。(Rac)-Indoximod 和 IFN-γ 联用显著降低了表达 α-SMA 的人心肌成纤维细胞活性,并通过上调 IRF-1,Fas 和 FasL 基因诱导凋亡(apoptosis)。
  • HY-100687
    GNF-PF-3777 Inhibitor
    GNF-PF-3777 (8-Nitrotryptanthrin) 是一种有效的人吲哚胺2,3-双加氧酶 2 (hIDO2) 抑制剂,有效降低 IDO2 活性,Ki 值为 0.97 μM。
  • HY-16987
    IDO-IN-3 Inhibitor 99.88%
    IDO-IN-3 是一种有效的吲哚胺-2,3-双加氧酶 (IDO) 抑制剂,IC50 为 290 nM。
  • HY-N0430
    Coptisine Inhibitor
    Coptisine 是从黄连中分离到的生物碱,是一种有效的非竞争性的 IDO 抑制剂,Ki 值为 5.8 μM,IC50 值为 6.3 μM。
  • HY-N2463
    Kushenol E Inhibitor
    Kushenol E 是从 Sophora flavescens 中分离出的一类类黄酮,是 IDO1 的非竞争性抑制剂,其 IC50 值为 7.7 µM,Ki 值为 9.5 µM,具有抗肿瘤活性。
  • HY-N0430A
    Coptisine Sulfate Inhibitor
    Coptisine Sulfate 是从黄连中分离到的生物碱,是一种有效的非竞争性的 IDO 抑制剂,Ki 值为 5.8 μM,IC50 值为 6.3 μM。
  • HY-N0110A
    Palmatine Inhibitor
    Palmatine 是一种口服活性的不可逆 IDO-1 抑制剂。Palmatine 可以减轻结肠损伤,预防肠道菌群失调和调节色氨酸分解代谢,从而改善DSS诱发的结肠炎。Palmatine 有潜力用于结肠炎的研究。
  • HY-111234
    IDO-IN-11 Inhibitor
    IDO-IN-11 是一个吲哚胺-2,3-双加氧酶 (IDO) 抑制剂,在激酶实验和Hela细胞实验中的 IC50 值分别为 0.18 和 0.014 μM, 来自专利 WO 2016041489 A1,化合物 13。
  • HY-112164B
    IACS-8968 S-enantiomer Inhibitor 98.43%
    IACS-8968 (S-enantiomer) 是 IACS-8968 的 S 型对映异构体。 IACS-8968 是 IDOTDO 的双抑制剂,其 pIC50s 值分别为 6.43,<5。
  • HY-112164A
    IACS-8968 R-enantiomer Inhibitor 98.48%
    IACS-8968 (R-enantiomer) 是 IACS-8968 的 R 型对映异构体。 IACS-8968 是 IDOTDO 的双抑制剂,其 pIC50s 值分别为 6.43,<5。
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.